Background/Aims: This study aimed to pathologically elucidate the roles of interleukin-12 receptor (IL-12R) beta 2 and interleukin-23 receptor (IL-23R) expression in tumor cells and tumorinfiltrating lymphocytes (TILs) in the tumor microenvironment and to determine their combined effect on prognosis of laryngeal cancer (LC). Methods: The tumor-cell expression scores and TIL positivity ratiosof IL-12R beta 2 and IL-23R in matched LC and normal laryngeal tissue samples from 61 LC patients were measured via immunohistochemistry (IHC). We adopted a linear regression model to analyze the correlation between IL-12R beta 2 and IL-23R expression in tumor cells and TIL ratios. TheKaplan-Meier log-rank test and Cox regression hazard ratios were used to analyze survival. Results: LC tumor cells had a higher IL-12R beta 2 expression and TIL ratio than IL-23R expression and TIL ratio. The significant correlations between IL-12R beta 2 and IL-23R expression and TIL ratios were identified in LC tissues, particularly in well-differentiated LC. Furthermore, either high tumor cell IL-12R beta 2 or low IL-23R expression had better survival than its corresponding low or high expression, respectively. Similar results did for IL-12R beta 2 ratio and IL-23R ratio. Finally, patients with both high IL-12R beta 2 and low IL-23R had the best prognosis among any other combined groups with both gene expression (HR, 0.1; 95% CI, 0.0-0.8). Likewise, patients with positive ratios of high IL-12R beta 2 and low IL-23R TILs had the best survival (HR, 0.1; 95% CI, 0.0-0.4). Conclusion: IL-12R beta 2 and IL-23R create a homeostasis within the tumor cells and TILs, and this homeostasis affects prognosis. While the intrinsic mechanisms of epigenetic immunoediting for IL-12R beta 2 and IL-23R remain unknown, additional larger and functional studies are warranted for validation. (C) 2018 The Author(s) Published by S. Karger AG, Basel